Clinical Trial Update: Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating zanubrutinib in combination with lenalidomide, with or without rituximab, in relapsed/refractory diffuse large B-cell lymphoma; results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Lenalidomide (lenalidomide)
• Rituximab (rituximab)
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: BeiGene | Conditions: Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Status: COMPLETED | Results posted: 2025-05-23